SCHEMBL4300725

SCHEMBL4300725

CCOCc1nc2c(N)ncc(C)c2n1NC(C)C

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 16/20 0.39
TLR8 Q9NR97 13/20 0.36
NUDT1 P36639 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4301417 0.81 TLR7 (0.40) TLR7TLR8NUDT1
SCHEMBL4753517 0.77 TLR7 (0.37) TLR7TLR8NUDT1
SCHEMBL4302529 0.77 TLR7 (0.47) TLR7TLR8NUDT1
SCHEMBL544735 0.76 TLR7 (0.62) TLR7TLR8NUDT1
SCHEMBL4299392 0.75 TLR7 (0.39) TLR7TLR8NUDT1
SCHEMBL4757773 0.73 TLR7 (0.55) TLR7TLR8NUDT1
SCHEMBL6093527 0.73 TLR8 (0.47) TLR7TLR8NUDT1
SCHEMBL6776799 0.73 TLR7 (0.39) TLR7TLR8NUDT1
SCHEMBL6783890 0.71 TLR7 (0.41) TLR7TLR8NUDT1
SCHEMBL4793672 0.71 TLR8 (0.41) TLR7TLR8NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed
WO-2006026760-A2 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS IL2, IL4I1, IFNG TLR7 188/4885TLR8 208/4885NUDT1 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.